Antibiotic Treatment for Urinary Tract Infections

First-Line Agents for Uncomplicated Cystitis

The American Urological Association recommends using nitrofurantoin, trimethoprim-sulfamethoxazole (TMP-SMX), or fosfomycin as first-line therapy for 3-7 days for uncomplicated UTIs in women, avoiding fluoroquinolones due to their unfavorable risk-benefit profile 1
For uncomplicated cystitis in women, the European Urology association suggests that TMP-SMX 160/800 mg twice daily for 3 days is a first-line option, but only if local resistance rates are <20% 1
The American Urological Association advises against using fluoroquinolones (ciprofloxacin, levofloxacin) as first-line therapy for uncomplicated UTIs due to FDA warnings about disabling and serious adverse effects, and recommends reserving them for when other effective options are unavailable or local resistance to first-line agents exceeds 10% 2, 3, 4

For outpatient management of mild-to-moderate pyelonephritis, the European Urology association recommends ciprofloxacin 500-750 mg twice daily for 7 days, levofloxacin 750 mg once daily for 5 days, trimethoprim-sulfamethoxazole 160/800 mg twice daily for 14 days, cefpodoxime 200 mg twice daily for 10 days, or ceftibuten 400 mg once daily for 10 days, only if local fluoroquinolone resistance is <10% 3, 5, 6, 7
When using oral cephalosporins empirically, the European Urology association suggests administering an initial intravenous dose of a long-acting parenteral antimicrobial (e.g., ceftriaxone 1-2 g) to ensure adequate initial coverage 3, 5

The European Urology association recommends that all UTIs in males be considered complicated, and suggests using ciprofloxacin 500-750 mg twice daily for 7-14 days, levofloxacin 750 mg once daily for 7-14 days, trimethoprim-sulfamethoxazole 160/800 mg twice daily for 14 days, or cefpodoxime 200 mg twice daily for 10-14 days, only if local resistance is <10% and the patient has not used fluoroquinolones in the past 6 months 4, 8
For complicated UTIs with systemic symptoms requiring hospitalization, the European Urology association recommends using combination intravenous therapy, such as amoxicillin plus an aminoglycoside, second-generation cephalosporin plus an aminoglycoside, or third-generation cephalosporin as monotherapy 4, 5

The American Academy of Pediatrics recommends that pediatric patients (2-24 months with febrile UTI) receive oral therapy, such as amoxicillin-clavulanate 20-40 mg/kg/day divided in 3 doses for 7-14 days, TMP-SMX 6-12 mg/kg trimethoprim component per day divided in 2 doses for 7-14 days, or cephalosporins, such as cefixime 8 mg/kg/day in 1 dose or cefpodoxime 10 mg/kg/day in 2 doses for 7-14 days 9
The American College of Obstetricians and Gynecologists advises obtaining urine culture and treating based on susceptibility results, avoiding fluoroquinolones and nitrofurantoin near term, in pregnant women 2

The European Urology association recommends avoiding single-dose therapy, as it shows significantly higher bacteriological persistence compared to 3-6 day courses or 7-14 day courses 1
The American Urological Association suggests that asymptomatic bacteriuria should not be treated in non-pregnant patients, as this increases the risk of symptomatic infection, bacterial resistance, and healthcare costs without benefit, except in pregnant women and patients scheduled for invasive urinary tract procedures 1, 2
The European Urology association advises considering local resistance patterns when selecting empiric therapy, as E. coli shows high persistent resistance to ampicillin, amoxicillin-clavulanate, and ciprofloxacin in many regions 2, 3, 4